NASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free VERA Stock Alerts $43.12 -0.71 (-1.62%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$42.38▼$44.4450-Day Range$14.93▼$49.1452-Week Range$5.95▼$50.78Volume666,497 shsAverage Volume1.29 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$32.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vera Therapeutics alerts: Email Address Vera Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside25.1% Downside$32.29 Price TargetShort InterestBearish16.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 17 Articles This WeekInsider TradingSelling Shares$36.25 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.21) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.35 out of 5 starsMedical Sector780th out of 938 stocksPharmaceutical Preparations Industry345th out of 417 stocks 2.5 Analyst's Opinion Consensus RatingVera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.29, Vera Therapeutics has a forecasted downside of 25.1% from its current price of $43.12.Amount of Analyst CoverageVera Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.23% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Vera Therapeutics has recently increased by 0.65%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERA. Previous Next 2.5 News and Social Media Coverage News SentimentVera Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Vera Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows11 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold 625.01% more of their company's stock than they have bought. Specifically, they have bought $4,999,990.00 in company stock and sold $36,250,598.00 in company stock.Percentage Held by Insiders22.60% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.21) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -18.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -18.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 15.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Vera Therapeutics Stock (NASDAQ:VERA)Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.Read More VERA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERA Stock News HeadlinesMarch 26, 2024 | insidertrades.comInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Sells 340,000 Shares of StockMarch 26, 2024 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Maha Katabi Sells 81,009 SharesMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 28, 2024 | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) Price Target Raised to $56.00 at GuggenheimMarch 27, 2024 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Buy" from BrokeragesMarch 26, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line DataMarch 26, 2024 | americanbankingnews.comMaha Katabi Sells 81,009 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockMarch 25, 2024 | americanbankingnews.comVera Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.46) Per Share, Wedbush Forecasts (NASDAQ:VERA)March 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 22, 2024 | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) Price Target Raised to $34.00March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed on Vera Therapeutics Ahead of Key Atacicept Clinical MilestonesMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vera Therapeutics with Promising Trials and Strong Financial RunwayMarch 20, 2024 | benzinga.comVera Therapeutics: Q4 Earnings InsightsMarch 20, 2024 | msn.comVera Therapeutics GAAP EPS of -$2.25 misses by $0.07March 20, 2024 | investorplace.comVERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023March 20, 2024 | globenewswire.comVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 17, 2024 | bbc.co.ukWeekend Woman’s Hour: Irish folk singer Cara Dillon, The Hampstead Paedophile Hoax, MaximalismMarch 16, 2024 | finance.yahoo.comVERA Mar 2024 17.500 callMarch 16, 2024 | ca.finance.yahoo.comVERA Apr 2024 40.000 callMarch 16, 2024 | finance.yahoo.comVERA Apr 2024 50.000 putMarch 14, 2024 | morningstar.comVera Therapeutics Inc Class A VERAMarch 14, 2024 | finance.yahoo.comRWE CEO: no plans for big, transformative dealsMarch 13, 2024 | nbcnews.comThe best foot peels for soft, smooth skin, according to expertsMarch 12, 2024 | msn.comAre foot peels safe? Derms weigh inMarch 6, 2024 | msn.comTop 10 best performing biotech stocks of 2024 so farFebruary 28, 2024 | globenewswire.comVera Therapeutics to Participate at the 44th Annual TD Cowen Health Care ConferenceFebruary 27, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VERA CUSIPN/A CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$32.29 High Stock Price Target$56.00 Low Stock Price Target$22.00 Potential Upside/Downside-25.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-68.25% Return on Assets-49.62% Debt Debt-to-Equity Ratio0.20 Current Ratio6.97 Quick Ratio6.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book15.57Miscellaneous Outstanding Shares52,497,000Free Float40,633,000Market Cap$2.26 billion OptionableOptionable Beta1.10 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Marshall Fordyce M.D. (Age 49)Founder, President, CEO & Director Comp: $828.89kMr. Sean P. Grant M.B.A. (Age 39)Chief Financial Officer Comp: $585.5kMr. Joseph R. Young M.B.A. (Age 51)Senior VP of Finance & Chief Accounting Officer Mr. Julien E. Capers J.D.VP & Head of LegalMs. Kelly RauberVP & Head of Human ResourcesMr. Tom Doan (Age 52)Senior Vice President of Development Operations Ms. Lauren Frenz (Age 39)Chief Business Officer Dr. Neeraj Pakala M.B.A.Ph.D., Senior VP and Head of Product Development & ManufacturingDr. Kerry Cooper M.D.Senior Vice President of Medical AffairsDr. Robert M. Brenner M.D. (Age 56)Chief Medical Officer More ExecutivesKey CompetitorsDyne TherapeuticsNASDAQ:DYNGalapagosNASDAQ:GLPGPTC TherapeuticsNASDAQ:PTCTMaravai LifeSciencesNASDAQ:MRVIAmphastar PharmaceuticalsNASDAQ:AMPHView All CompetitorsInsiders & InstitutionsMaha KatabiSold 340,000 sharesTotal: $13.77 M ($40.50/share)Maha KatabiSold 81,009 sharesTotal: $3.58 M ($44.20/share)Vanguard Group Inc.Bought 59,218 shares on 3/11/2024Ownership: 3.112%Goldman Sachs Group Inc.Bought 229,414 shares on 3/1/2024Ownership: 1.237%GSA Capital Partners LLPBought 22,620 shares on 2/16/2024Ownership: 0.100%View All Insider TransactionsView All Institutional Transactions VERA Stock Analysis - Frequently Asked Questions Should I buy or sell Vera Therapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VERA shares. View VERA analyst ratings or view top-rated stocks. What is Vera Therapeutics' stock price target for 2024? 8 analysts have issued 1 year price targets for Vera Therapeutics' stock. Their VERA share price targets range from $22.00 to $56.00. On average, they anticipate the company's share price to reach $32.29 in the next year. This suggests that the stock has a possible downside of 25.1%. View analysts price targets for VERA or view top-rated stocks among Wall Street analysts. How have VERA shares performed in 2024? Vera Therapeutics' stock was trading at $15.38 at the start of the year. Since then, VERA stock has increased by 180.4% and is now trading at $43.12. View the best growth stocks for 2024 here. When is Vera Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VERA earnings forecast. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.33. What ETF holds Vera Therapeutics' stock? Invesco Dorsey Wright Healthcare Momentum ETF holds 98,152 shares of VERA stock, representing 1.01% of its portfolio. When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO. Who are Vera Therapeutics' major shareholders? Vera Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Kynam Capital Management LP (6.95%), Vanguard Group Inc. (3.11%), Vanguard Group Inc. (3.11%), Schroder Investment Management Group (2.12%), Point72 Asset Management L.P. (1.88%) and Goldman Sachs Group Inc. (1.24%). Insiders that own company stock include Beth C Seidenberg, Carlyle Group Inc, Celia Lin, Commodore Capital Lp, Joanne Curley, Llp Abingworth, Maha Katabi, Marshall Fordyce, Patrick G Enright, Sean Grant and Sofinnova Venture Partners X,. View institutional ownership trends. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.